AEGiS-UPI: Vaginal microbicide undergoes safety trial United Press InternationalImportant note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Click here to return to United Press International main menu
DonateNow
Print this article




Vaginal microbicide undergoes safety trial

United Press International -- November 30, 2006


DAVIS, Calif. (UPI) -- Researchers are seeking participants for the first U.S. study of the safety of a new vaginal gel designed to prevent herpes and HIV infection.

The University of California-Davis scientists say if the gel is found effective and approved by the U.S. Food and Drug Administration, it would become an important weapon in the fight against HIV since it would allow women to protect themselves from infection rather than relying on their partners to use condoms.

"The significance of the gel is that it potentially gives the power back to the woman to protect herself against infection," said Dr. Anna-Barbara Moscicki, professor of pediatrics and lead investigator for the study.

The gel -- brand name VivaGel -- is not a contraceptive, but a microbicide that is inserted into the vagina solely to prevent the spread of HIV and other sexually transmitted diseases. There are currently no such products on the market.

Following the safety research, other trials will be conducted to determine its effectiveness at fighting herpes and HIV infection. But Moscicki said previous trials in animals have found the gel to be nearly 100 percent effective, with few side effects.
061130
UP061139


Copyright © 2006 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .